Clinical data | |
---|---|
Pronunciation | /ˌɛtoʊˈpoʊsaɪd/ |
Trade names | Etopophos, Toposar, Vepesid, others |
Other names | VP-16; VP-16-213 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684055 |
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Highly variable, 25 to 75% |
Protein binding | 97% |
Metabolism | Liver (CYP3A4 involved) |
Elimination half-life | Oral: 6 h., IV: 6-12 h., IV in children: 3 h. |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.812 |
Chemical and physical data | |
Formula | C29H32O13 |
Molar mass | 588.562 g·mol−1 |
3D model (JSmol) | |
Melting point | 243.5 °C (470.3 °F) |
| |
| |
(verify) |
Etoposide, sold under the brand name Vepesid among others, is a chemotherapy medication used for the treatments of a number of types of cancer including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer.[2] It is also used for hemophagocytic lymphohistiocytosis.[3] It is used by mouth or injection into a vein.[2]
Side effects are very common.[2] They can include low blood cell counts, vomiting, loss of appetite, diarrhea, hair loss, and fever.[2] Other severe side effects include allergic reactions and low blood pressure.[2][4] Use during pregnancy will likely harm the fetus.[2] Etoposide is in the topoisomerase inhibitor family of medication.[2] It is believed to work by damaging DNA.[2]
Etoposide was approved for medical use in the United States in 1983.[2] It is on the World Health Organization's List of Essential Medicines.[5]